In the past week, CRBU stock has gone up by 3.09%, with a monthly gain of 7.85% and a quarterly plunge of -23.69%. The volatility ratio for the week is 10.22%, and the volatility levels for the last 30 days are 8.17% for Caribou Biosciences Inc The simple moving average for the past 20 days is 17.27% for CRBU’s stock, with a -11.68% simple moving average for the past 200 days.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
, and the 36-month beta value for CRBU is at 2.11. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price suggested by analysts for CRBU is $22.00, which is $17.33 above the current market price. The public float for CRBU is 75.96M, and currently, shorts hold a 12.88% of that float. The average trading volume for CRBU on November 16, 2023 was 1.61M shares.
CRBU) stock’s latest price update
Caribou Biosciences Inc (NASDAQ: CRBU)’s stock price has plunge by 10.66relation to previous closing price of 4.22. Nevertheless, the company has seen a 3.09% surge in its stock price over the last five trading sessions. The Motley Fool reported 2023-10-10 that Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou’s lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.
CRBU Trading at 1.35% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.07% of loss for the given period.
Volatility was left at 8.17%, however, over the last 30 days, the volatility rate increased by 10.22%, as shares surge +14.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.57% lower at present.
During the last 5 trading sessions, CRBU rose by +3.09%, which changed the moving average for the period of 200-days by -35.23% in comparison to the 20-day moving average, which settled at $4.01. In addition, Caribou Biosciences Inc saw -25.64% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CRBU starting from Rizvi Syed Ali-aamir, who sale 5,627 shares at the price of $6.31 back on Jan 19. After this action, Rizvi Syed Ali-aamir now owns 59,373 shares of Caribou Biosciences Inc, valued at $35,506 using the latest closing price.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -768.17 for the present operating margin
- +73.71 for the gross margin
The net margin for Caribou Biosciences Inc stands at -717.79. The total capital return value is set at -29.69, while invested capital returns managed to touch -27.79. Equity return is now at value -26.18, with -22.08 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 9.22 points at debt to equity in total, while total debt to capital is 8.44. Total debt to assets is 7.22, with long-term debt to equity ratio resting at 8.90. Finally, the long-term debt to capital ratio is 8.15.
When we switch over and look at the enterprise to sales, we see a ratio of 4.43, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 2.17 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.25.
In conclusion, Caribou Biosciences Inc (CRBU) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.